Kinnate Biopharma Q2 FY23: diluted EPS −$0.68

Key figures from this report

These are the numbers Kinnate Biopharma reported for Q2 FY23, the quarter ended Jun 30, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Diluted EPS−$0.68Against −$0.62 in Q2 FY2210-Q income statement, on EDGAR
2. Cash and cash equivalents$34.5M−2% from $35.1M in Q2 FY22Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
3. Cash from operations−$29.4MAgainst −$23.5M in Q2 FY2210-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters